Article Sidebar

Published: 2026-08-25
Abstract Views: 0
DOI: https://doi.org/10.52163/yhc.v67iCD12.6370
Issue
Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026)
Section
Articles
How to Cite
Giáp, V. Đình, Lợi, C. B., Chỉnh, D. ĐÌnh, & Nhật, Đoàn T. H. (2026). CLINICAL, HISTOPATHOLOGICAL, AND BRCA1/2 MUTATION CHARACTERISTICS IN BREAST CANCER PATIENTS TREATED AT NGHE AN ONCOLOGY HOSPITAL. Vietnam Journal of Community Medicine, 67(Số CĐ12- Bệnh viện Ung bướu Nghệ An). https://doi.org/10.52163/yhc.v67iCD12.6370

CLINICAL, HISTOPATHOLOGICAL, AND BRCA1/2 MUTATION CHARACTERISTICS IN BREAST CANCER PATIENTS TREATED AT NGHE AN ONCOLOGY HOSPITAL

Vu Dinh Giap1, Cao Ba Loi2, Duong Dinh Chinh2, Doan Thi Hong Nhat3
1 Nghe An Oncology Hospital
2 National Institute of Malariology, Parasitology and Entomology
3 Vinh Medical University

Main Article Content

Abstract

Objective: To describe the clinical and histopathological characteristics and BRCA1/2 mutation profiles in breast cancer patients treated at Nghe An Oncology Hospital.


Methods: A cross-sectional descriptive study with analytical components was conducted among 373 breast cancer patients treated at Nghe An Oncology Hospital between 2024 and 2025. High-risk patients underwent next-generation sequencing (NGS) to identify BRCA1/2 mutations.


Results: Tumors were more frequently located in the right breast (52.55%), with the upper outer quadrant being the most common tumor location (56.3%). Stage II disease accounted for the largest proportion of cases (54.4%). Invasive ductal carcinoma was the predominant histopathological type (83.9%), and histological grade II accounted for the majority of cases (77.47%). Luminal B/HER2-negative was the most common molecular subtype. BRCA1/2 genetic analysis identified pathogenic or likely pathogenic (P/LP) variants in 10 high-risk patients (9.7%), including four patients (3.9%) with BRCA1 variants and six (5.8%) with BRCA2 variants. The most frequently detected mutation was NM_000059.4:c.6490C>T (p.Gln2164Ter), located in exon 11 of BRCA2. The P/LP variants identified in BRCA1 and BRCA2 were protein-truncating variants that were expected to affect the structure or function of the BRCA1/2 proteins. These variants were supported by strong evidence of pathogenicity according to the ACMG/AMP criteria, including PVS1 and PM2, and had been reported in ClinVar with multiple submissions or previously classified as pathogenic.


Conclusions: Breast cancer patients treated at Nghe An Oncology Hospital were predominantly diagnosed with stage II disease, and invasive ductal carcinoma was the most common histopathological type. Among 103 high-risk patients who underwent genetic testing, 10 (9.7%) carried P/LP variants in BRCA1/2, including four patients with BRCA1 variants and six with BRCA2 variants.

Article Details

Keywords

Breast cancer; BRCA1; BRCA2; histopathology; Nghe An Oncology Hospital. .

References

[1] H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians, vol. 71, no. 3, pp. 209–249, 2021, doi: 10.3322/caac.21660.
[2] V. Barili et al., “Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing,” Genes (Basel), vol. 15, no. 2, p. 219, Feb. 2024, doi: 10.3390/genes15020219.
[3] Y. Feng et al., “Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis,” Genes Dis, vol. 5, no. 2, pp. 77–106, May 2018, doi: 10.1016/j.gendis.2018.05.001.
[4] Phạm H. K., Mai T. Đ., and Dương M. L., “ĐÁNH GIÁ ĐỘT BIẾN GEN BRCA1, BRCA2 TRÊN BỆNH NHÂN UNG THƯ VÚ CÓ NGUY CƠ CAO TẠI BỆNH VIỆN K,” VMJ, vol. 519, no. 2, Nov. 2022, doi: 10.51298/vmj.v519i2.3677.
[5] Toàn T. T., Lan T. T. H., Linh N. T. T., Linh V. D., and Quang N. N., “BƯỚC ĐẦU NGHIÊN CỨU TÌNH TRẠNG ĐỘT BIẾN BRCA1/2 TRONG UNG THƯ VÚ BẰNG KỸ THUẬT GIẢI TRÌNH TỰ GEN THẾ HỆ MỚI TẠI BỆNH VIỆN K, Tạp chí Y học Việt Nam, Tập 521, trang 255-262.,” 2022.
[6] Somal R và cs. (2023). Molecular subtypes of breast cancer and clinicopathological characteristics in breast cancer patients. Asian Pacific Journal of Cancer Prevention.
[7] Đăng N. L. H. et al., “Tần suất và phổ đột biến gen của Hội chứng ung thư vú và buồng trứng di truyền trên quần thể người Việt Nam,” 1, vol. 20, no. 3, pp. 130–135, Oct. 2022, doi: 10.46755/vjog.2022.3.1433.
[8] X. Yu, C. C. S. Chini, M. He, G. Mer, and J. Chen, “The BRCT domain is a phospho-protein binding domain,” Science, vol. 302, no. 5645, pp. 639–642, Oct. 2003, doi: 10.1126/science.1088753.
[9] M. Rodriguez, X. Yu, J. Chen, and Z. Songyang, “Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains,” J Biol Chem, vol. 278, no. 52, pp. 52914–52918, Dec. 2003, doi: 10.1074/jbc.C300407200.
[10] M. K. K. Shivji, O. R. Davies, J. M. Savill, D. L. Bates, L. Pellegrini, and A. R. Venkitaraman, “A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange,” Nucleic Acids Res, vol. 34, no. 14, pp. 4000–4011, 2006, doi: 10.1093/nar/gkl505.
[11] P. R. Andreassen, J. Seo, C. Wiek, and H. Hanenberg, “Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses,” Genes (Basel), vol. 12, no. 7, p. 1034, Jul. 2021, doi: 10.3390/genes12071034.
[12] M. T. Parsons et al., “Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel,” Am J Hum Genet, vol. 111, no. 9, pp. 2044–2058, Sep. 2024, doi: 10.1016/j.ajhg.2024.07.013.